Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.62 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.62 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.62 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.60 |
| ▸ | SRM | P19623 | 3/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007640 | 0.93 | DOT1L (0.65) | DOT1LDNMT3BPRMT7P2RY1SRM | |
| SCHEMBL10886673 | 0.89 | DOT1L (0.66) | DOT1LDNMT3BPRMT7P2RY1SRM | |
| SCHEMBL31001584 | 0.84 | P2RY1 (0.61) | DOT1LDNMT3BPRMT7P2RY1SRM | |
| SCHEMBL4819105 | 0.83 | P2RY1 (0.70) | P2RY1ADORA1SMN1; SMN2P2RY2SRC | |
| SCHEMBL1513014 | 0.83 | P2RY1 (0.77) | P2RY1ADORA1SMN1; SMN2P2RY2SRC | |
| SCHEMBL6247323 | 0.82 | AHCY (0.71) | DOT1LP2RY1ADORA1SMN1; SMN2P2RY2 | |
| SCHEMBL6828798 | 0.82 | ADORA1 (0.70) | DOT1LDNMT3BPRMT7P2RY1ADORA1 | |
| SCHEMBL8388991 | 0.82 | DOT1L (0.66) | DOT1LDNMT3BPRMT7P2RY1SRM | |
| SCHEMBL481524 | 0.82 | ADORA1 (0.76) | DOT1LP2RY1ADORA1SMN1; SMN2P2RY2 | |
| SCHEMBL2040670 | 0.82 | ADORA1 (0.76) | DOT1LP2RY1ADORA1SMN1; SMN2P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151975-A1 | DETECTING DEGRADATION OF A POLYNUCLEOTIDE BY RAMAN SPECTROSCOPY | LEDNEV IGOR (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11980672-B2 | Heterologous UTR sequences for enhanced mRNA expression | MODERNATX, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4351623-A1 | GENE COMBINATION AS A BROAD SPECTRUM ANTIVIRAL | Icahn School of Medicine at Mount Sinai (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240100188-A1 | REGULATORY SYSTEM FOR EXPRESSION OF A GENE OF INTEREST IN A TARGET CELL AND METHOD OF USE THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024015729-A1 | REGULATORY SYSTEM FOR EXPRESSION OF A GENE OF INTEREST IN A TARGET CELL AND METHOD OF USE THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023235568-A1 | DERIVATION OF GLUCOSE-RESPONSIVE INSULIN-SECRETING CELLS AND ORGANOIDS FROM HUMAN STOMACH CELLS AND THEIR USE TO TREAT DIABETES | CORNELL UNIVERSITY (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023192932-A2 | INDUCED LIVER SINUSOIDAL ENDOTHELIAL CELLS (iLSECs) AND METHODS FOR SUPPORTING HEPATOCYTES USING THE iLSECs | CORNELL UNIVERSITY (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230050143-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | MODERNATX, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230008266-A1 | SYNTHETIC MODIFIED RNA AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-12 | — | — | US | disclosed |
| WO-2022261206-A1 | GENE COMBINATION AS A BROAD SPECTRUM ANTIVIRAL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-3423106-A1 | BIODEGRADABLE ACTIVATED POLYMERS FOR THERAPEUTIC DELIVERY | Alexion Pharmaceuticals, Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180353618-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | MODERNATX, INC. (US) | 2018-12-13 | — | — | US | disclosed |
| US-10138507-B2 | Manufacturing methods for production of RNA transcripts | MODERNATX, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-3386533-A1 | MODIFIED MRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF | ModernaTX, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017100562-A9 | MODIFIED MRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF | ALEXION PHARMACEUTICALS, INC, (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017100562-A1 | MODIFIED MRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF | ALEXION PHARMACEUTICALS, INC, (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100551-A1 | HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION | ALEXION PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20160024547-A1 | MANUFACTURING METHODS FOR PRODUCTION OF RNA TRANSCRIPTS | ARES CAPITAL CORPORATION, AS AGENT | 2016-01-28 | — | — | US | disclosed |
| EP-2971033-A1 | MANUFACTURING METHODS FOR PRODUCTION OF RNA TRANSCRIPTS | Moderna Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152027-A1 | MANUFACTURING METHODS FOR PRODUCTION OF RNA TRANSCRIPTS | MODERNA THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050143-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | RNGTT, UPF1, RNMT | DOT1L 4741/4885DNMT3B 1310/4885PRMT7 2667/4885 |
| US-20180353618-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | RNGTT, UPF1, RNMT | DOT1L 4741/4885DNMT3B 1310/4885PRMT7 2667/4885 |
| US-11980672-B2 | Heterologous UTR sequences for enhanced mRNA expression | RNGTT, UPF1, RNMT | DOT1L 4741/4885DNMT3B 1310/4885PRMT7 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.